When given as treatment for advanced cancer of the breast, combination chemotherapy results in complete or partial remissions in more than 50% of patients. At this time the tumour burden is usually large and the patients often debilitated. Experimients with transplantable tumours in animals indicate that the potential for cure using chemotherapy is inversely proportional to the tumour burden (Skipper, 1978) . This led to the concept of administration of chemotherapy as an adjuvant to surgery, after mastectomy, when the tumour burden is at its lowest and the patient fit. Other possible advantages of this approach are that small tumours are likely to be well vascularised and theoretically less likely to have become spontaneously resistant to chemotherapy (Goldie & Coldman, 1979) .
In terms of response, combinations of drugs are more effective for the treatment of advanced breast cancer than single agents. The first trial of adjuvant combination chemotherapy was performed in Milan using cyclophosphamide, methotrexate and fluorouracil (Bonadonna et al., 1976) . The early results of this study showed a highly significant reduction in the time to first relapse, particularly in premenopausal women, and led us to set up the trial reported here.
The aim of this study was to confirm the Milan results and to attempt to improve on them. We, therefore, chose to use a combination of drugs which included adriamycin as the most active single agent in breast cancer; to use a combination known to be effective in the treatment of advanced breast cancer (Price et al., 1983) and to administer the drugs in the adjuvant situation without reduction of the dose. Also we wished to begin injections as soon as possible after mastectomy in view of the results of a trial conducted by NissenMeyer et al. (1978) , which suggested an advantage for early treatment.
The trial was started in December 1976 as a multicentre study within the West Midlands region of the United Kingdom. Preliminary analyses of the study were reported when the median follow-up times were 22, 54 and 60 months (Morrison et al., 1981 (Morrison et al., , 1984 (Morrison et al., , 1987 . This paper presents a more complete analysis of the trial 10 years after recruitment began when the median follow-up was 7 years. 
Patients and methods

Selection ofpatients
Treatment
Following histological confirmation of the diagnosis all patients had a simple mastectomy with axillary node sampling (Forrest et al., 1976 (Elston et al., 1982) was a modification of the system developed by Bloom and Richardson (1957) . Oestrogen and progesterone receptors were assayed using the dextran coated charcoal method and Scatchard analysis (McGuire & De La Garza, 1973 (Peto et al., 1977) . However, since there was no notification by clinicians of disease status for patients who were randomised but were found subsequently to be ineligible, only eligible patients are included in the analysis of recurrence, relapse-free survival and toxicity. Relapse-free survival and overall survival curves were drawn using the method of Kaplan and Meier (1958) and the significance of the differences between curves assessed using the log rank test (Peto et al., 1977) . Treatment comparisons were stratified by menopausal status and tumour size. In addition the effect of controlling for menopausal status, tumour size, age, tumour grade and receptor content was determined using Cox's multiple regression analysis (Cox, 1972) . The reduction in the odds of relapse and death (Early Breast Cancer Trialists' Collaborative Group, 1988) patients. However, the other analyses are based on only 539 patients. One treated patient cannot be included because she was completely lost to follow-up. Twenty-nine patients were found, on review (K.A.K.), to be ineligible (17 treated and 12 control) and are excluded since they were not followed up. Patients were excluded after randomisation for the following reasons; advanced disease (six treated, three control), >65 years of age (four treated, one control), abnormal liver function tests (one treated, seven control), intercurrent disease (three treated), node negative (two treated, one control) and lymphoma (one treated). The characteristics of the patients eligible for analysis of relapse and toxicity are given in Table  I , which shows that there are no major imbalances of prognostic factors between the treated and control groups.
Relapse-free survival Adjuvant chemotherapy significantly prolonged relapse free survival ( Figure 1 , Table II ). After stratification for menopausal status and tumour size, X21 is 11.9 (P = 0.0006).
Controlling for menopausal status, tumour size, age, tumour grade or receptor status does not substantially alter this treatment effect.
The percentage relapse free at 5 years is improved by treatment from 27% to 38% (with confidence intervals of 21-33% and 32-44% respectively) and represents a relative improvement (RI) of 42% ((38-27)/27) in relapse rate or a 30% reduction in the odds of relapse (OR). The median prolongation of relapse free survival is 14 months, from 628 days to 1,057 days (with confidence intervals of 554-808 days and 836-1,290 days respectively).
There were 181 (66%) patients who recurred in the treated group and 199 (76%) in the control group. There was no significant difference in the distribution of metastases between the treatment and control groups (X21 = 0.18; P= 0.67; Table III ). domised to treatment received no chemotherapy. The reasons for not receiving the full course of eight cycles of chemotherapy were toxicity (22%), intercurrent illness not associated with treatment (15%), patient refusal (37%) and administrative errors mainly involving failure to give the eighth cycle (26%).
Toxicity
The proportion of patients affected and the number of cycles in which toxic effects were seen are summarised in Table VI mon. In particular, there were no episodes of cardiac failure.
had toxicity. Patients we The severity and duration of nausea and vomiting are of cycles patients took t outlined in Figure 4 . Severe symptoms were uncommon.
confined to bed for a v However, when symptoms occurred, they lasted for longer than 24h in approximately half the cycles assessed. An assessment of the 'quality of life' of patients is shown in Figure 4 . Patients were asked how long they were unwell, Second primary tumoui how long they were unable to go to work (or perform (cervix, rectum) and thre housework) and how long they were confined to bed if they oesophagus). No leukae ere unwell in 58% of cycles. In 37% time off work and in 30% they were variable period.
irs occurred in two of the control ee of the treated group (cervix, lung, mias have been recorded. 
Discussion
This study shows that administration of eight cycles of AVCMF after mastectomy to women with axillary node involvement delays local and distant relapse by a median of 14 months. This difference in relapse-free survival has not been translated into an equivalent advantage in overall survival. It was hoped that the addition of adriamycin and vincristine to CMF would enhance the therapeutic effect; our results do not show a greater effect at this stage of follow-up compared with CMF trials. At a median follow-up of 7 years, 50% of patients have died. These deaths are in women who presumably had undetected but extensive micrometastatic disease present at mastectomy and who would therefore be expected to recur early after surgery. It remains to be seen whether the more intensive chemotherapy reported here will affect survival in patients presumed to have a small micrometastatic burden at mastectomy. This group would be expected to have a later recurrence and death and possibly be the very patients to benefit from adjuvant chemotherapy.
In this study not all patients randomised to treatment received chemotherapy; eleven ineligible patients (3.7%) may not have had chemotherapy and eight patients (2.7%), although eligible, did not receive any treatment, usually due to patient refusal. Analysis of survival with or without these groups does not alter the result.
The i -7 n months for all patients: 17 months in the premenopausal group and 8 months in the post-menopausal group. It is clearly difficult to make judgements concerning the trade off in cost related to the toxicity and inconvenience of chemotherapy and benefit related to the increased period free from recurrence of disease. The treatment was relatively myelosuppressive but there were no infective or other toxic deaths. There were no episodes of cardiac failure, although the total dose of adriamycin (400 mg) was well below that which can produce cardiotoxicity and the trial was confined to patients below age 65 because of this potential risk. Just over half of the cycles of chemotherapy were associated with symptoms of toxicity and in half of these, the symptoms lasted for more than 24 h. Thus, in chemotherapy term, this regimen of treatment is relatively non-toxic.
The significance of A VCMF in relation to other trials The results of our trial must be set in the context of the Early Breast Cancer Trialists' Collaborative Group (1988) 'overview' of all trials of combination chemotherapy with a no treatment control arm. In the overview, trials of combination chemotherapy were divided into three groups: CMF regimens, CMF regimens with extra cytotoxic agents and regimens without some or all of C, M, F. The trial reported here falls into the group of CMF regimens with extra cytotoxic agents. It is the only study in the group with more than 150 patients randomised, where the data are available and where there is adequate follow-up. Patients from this trial represent 39% (569/1,467) of those analysed in this group. The results from this trial are consistent with the overview for this group which shows a highly significant improvement in relapse-free survival and a clear survival advantage in young women, but no clear survival advantage in older women. The overview shows a reduction in the odds of relapse of 30% both for this group and for all polychemotherapy trials; in this analysis the odds reduction is also 30%. The reduction in the odds of death of 26% in young women shown for our trial in the overview is similar to the average reduction of 20% for all trials in this group and the same as the overall average for all polychemotherapy trials of 26%. With a median of 7 years follow-up the odds reduction is now 16%.
This regimen, with a reduction in the odds of death of 26% in the overview, appears to be intermediate in effectiveness between CMF (OR = 37%) and other multiple agents (OR = 12%), and is very close to the overall average improvement of 26% reported for all polychemotherapy trials and 22% for all chemotherapy trials. Care must be taken when comparing groups of chemotherapies. The overview shows no significant heterogeneity between the chemotherapy trials reported, so that such comparisons between groups of chemotherapies must be regarded as useful for the generation of hypotheses, rather than being definitive.
Steroid hormone receptors ER and PR were measured on 69% and 55% of tumours. Analysis showed no significant relationship between ER and relapse-free survival and overall survival whereas there was a significant effect of chemotherapy upon relapse-free survival but not overall survival in patients with PR positive tumours (Table II) . This appeared to be mainly in the premenopausal group (Table IV) (Bonadonna et al., 1985) Guys/Manchester CMF + + (PR) Padmanabhan et al., 1986) This supports the association in this study between PR positive tumours and prolonged relapse free survival and is consistent with a partial endocrine effect of chemotherapy.
However, there was also an effect in grade III tumours overall but this failed to reach conventional significance levels (P = 0.06). These results are not consistent with other studies. Fisher et al. (1986) reported that melphalan was active only in women with grade III tumours. Brinckler et al. (1987) showed that CMF was equally active in women with grade II and grade III tumours, but was inactive in women with grade I tumours. It is not clear why the results of the three studies should be as divergent: it is likely that it is an effect of small numbers and the subjectiveness of grading. The latter was standardised in this report by having a single pathologist look at all the slides.
Conclusion
Taken in isolation the results presented here would not give a clear indication for the general use of adjuvant chemotherapy in node positive breast cancer. A useful prolongation of relapse-free survival was seen in premenopausal women, but that seen in post-menopausal women was approximately equivalent to the duration of treatment with chemotherapy after surgery. It will be important to determine whether this high risk group of young women fare better when given adjuvant chemotherapy compared with adjuvant endocrine therapy: there is clearly a need for clinical trials to compare the effects of each treatment. However, greater improvements in survival will only come with improved chemotherapy or the introduction of entirely new treatments. The effectiveness of adjuvant chemotherapy might be improved by increasing the intensity of treatment, possibly with haemopoietic growth factors, by giving treatment early, possibly even before surgery and by developing new agents. It is in our view preferable to examine these important factors in well planned clinical trials than to recommend prematurely the use of adjuvant chemotherapy in routine clinical practice, particularly in post-menopausal women.
